Xeris Biopharma Holdings

XERS

Market cap $1.19B

Overview Fund Activity

7.36 USD

-0.13

1.74%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

7.20

-0.16

2.17%

1 day

-1.74%

5 days

-5.4%

1 month

-4.17%

3 months

67.27%

6 months

46.32%

Year to date

112.72%

1 year

155.56%

5 years

32.61%

10 years

-63.6%

About: Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Employees: 394

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

165% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $384K

36% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 58

13% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 24

1.53% more ownership

Funds ownership: 56.39% [Q1] → 57.91% (+1.53%) [Q2]

1% more funds holding

Funds holding: 199 [Q1] → 201 (+2) [Q2]

11% less capital invested

Capital invested by funds: $477M [Q1] → $423M (-$53.6M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

9% upside

Avg. target

$9.5

29% upside

High target

$11

49% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Leerink Partners Roanna Ruiz	$9	Outperform Maintained	19 Aug 2025
HC Wainwright & Co. Brandon Folkes	$10	Buy Assumed	12 Aug 2025
Craig-Hallum Chase Knickerbocker	$11	Buy Maintained	8 Aug 2025
Oppenheimer Leland Gershell	$8	Outperform Maintained	8 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about XERS published over the past 30 days

Zacks Investment Research

What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?

Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?

Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady diversification; Keveyis' contribution is expected to continue declining. XP-8121, a once-weekly levothyroxine, offers significant long-term upside but introduces future funding risks for Phase 3 trials.

Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and that this patent is now listed in the publication, “Approved Drug Products with Therapeutics Equivalence Evaluations,” common.

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Zacks Investment Research

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

Zacks Investment Research

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

The Motley Fool

Xeris (XERS) Q2 Revenue Jumps 49%

Xeris (XERS) Q2 Revenue Jumps 49%

Xeris (XERS) Q2 Revenue Jumps 49%

Zacks Investment Research

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

Xeris Biopharma (XERS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. “Total revenue in the second quarter increased almost 50% year-over-year to a record $72 million, driven by increased patient demand across all three.

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

See News Rankings

Charts implemented using Lightweight Charts™